FDA grants Capricor flexibility on Duchenne drug trial after advisory panel setback

A family recounts how their son with Duchenne muscular dystrophy has lived independently while participating in Capricor's deramiocel trial, now preparing for a master's program. The drug's recent FDA advisory committee vote was unfavorable on a secondary measure of heart function, noting inconsistent data across participants. The panel's criticism underscores how minute design choices—such as inclusion criteria and outcome selection—can sway statistical significance and enrollment feasibility.

Recognizing the urgency for patients, the FDA chose to let Capricor submit extra upper-limb performance data and re-analyze the primary endpoint. This regulatory flexibility aims to balance rigorous pre-specification with the practical realities of rare-disease research. Experts like Mindy Leffler, who helped develop the Duchenne Video Assessment used in the study, stress the need for careful analysis to truly gauge treatment impact.